Pharmacogenomics in Molecular Oncology
作者： Soya S. Sam , Gregory J. Tsongalis
DOI: 10.1007/978-1-4899-8050-2_24
关键词:
摘要: In the past decade, substantial advances in pharmacogenomics have increasingly unveiled genetic basis of interindividual differences drug responses. Majority these been made field oncology which revolutionized cancer therapy. Pharmacogenomics plays a significant role pharmacotherapy as narrow therapeutic indices, variable response rates, rapid and severe systemic toxicity, unpredictable efficacy are all hallmarks therapies. Personalized oncologic care is becoming trend because constant advancement clinical molecular diagnostics biomarker discoveries. addition, intricate mechanisms that provoke neoplastic cell transformation along with dysregulation alternative complementary pathways understood. This review discusses current commonly used predictive prognostic biomarkers testing.
springer.com
sci-hub.st 参考文章(118)
Cong Tan, Xiang Du, KRAS mutation testing in metastatic colorectal cancer World Journal of Gastroenterology. ,vol. 18, pp. 5171- 5180 ,(2012) , 10.3748/WJG.V18.I37.5171
HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz, Chronic myelogenous leukemia: a concise update Blood. ,vol. 82, pp. 691- 703 ,(1993) , 10.1182/BLOOD.V82.3.691.691
Jan Siehl, Eckhard Thiel, C-kit, GIST, and Imatinib Targeted Therapies in Cancer. ,vol. 176, pp. 145- 151 ,(2007) , 10.1007/978-3-540-46091-6_12
Motulsky A, From pharmacogenetics and ecogenetics to pharmacogenomics. Medicina nei secoli. ,vol. 14, pp. 683- 705 ,(2002)
S. Rod Rassekh, Michael R. Hayden, Bruce Carleton, Colin J.D. Ross, Lucila I. Castro-Pastrana, Evan Shereck, Henk Visscher, PHARMACOGENOMICS OF SERIOUS ADVERSE DRUG REACTIONS IN PEDIATRIC ONCOLOGY Journal de la thérapeutique des populations et de la pharamcologie clinique. ,vol. 18, ,(2011)
Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth, David H. Harrington, Karl S. Theil, Anwar Mohamed, Elizabeth Paietta, Cheryl L. Willman, David R. Head, Jacob M. Rowe, Stephen J. Forman, Frederick R. Appelbaum, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood. ,vol. 96, pp. 4075- 4083 ,(2000) , 10.1182/BLOOD.V96.13.4075
ME Huang, YC Ye, SR Chen, JR Chai, JX Lu, L Zhoa, LJ Gu, ZY Wang, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood. ,vol. 72, pp. 567- 572 ,(1988) , 10.1182/BLOOD.V72.2.567.567
S Misawa, S Horiike, K Kashima, H Kaneko, T Iwai, M Nakao, S Yokota, T Fujimoto, Y Sonoda, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. ,vol. 10, pp. 1911- 1918 ,(1996)
Elias Campo, N Lee Harris, Elaine S Jaffe, Stefano A Pileri, Harald Stein, Jurgen Thiele, James W Vardiman, None, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ,(2017)
Gabriel Capellà, Lourdes Farré, Isolda Casanova, Adela Mazo, Sílvia Guerrero, Ramon Mangues, K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Research. ,vol. 60, pp. 6750- 6756 ,(2000)